
Full text loading...
Category: Clinical Microbiology
RNA Respiratory Viruses, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815455/9781555813970_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555815455/9781555813970_Chap07-2.gifAbstract:
RNA respiratory viruses, including influenza virus, respiratory syncytial virus (RSV), parainfluenza virus (PIV), human metapneumovirus (hMPV), human rhinovirus (HRV), and coronavirus (CoV), are increasingly being recognized as causing significant morbidity, graft failure, and death among immunocompromised patient populations. Respiratory viral infections are associated with increased risk of death, development of viral pneumonia, and coinfections, particularly bacterial pneumonia and invasive aspergillosis. Respiratory viral infections are associated with both acute and chronic rejection. Antiviral resistance is an emerging issue among immunocompromised patients infected with influenza virus, although resistance testing is not yet widely available outside the research setting. Unlike the case for RSV and influenza virus, no rapid antigen test kits are available for detection of PIV. There are several monoclonal antibody (MAb) systems that allow for identification and differentiation of the different PIV serotypes in primary patient samples and in cell cultures. There are currently five clinically significant human coronaviruses recognized, namely, OC43, 229E, NL63, HKU1, and severe acute respiratory syndrome CoV (SARS-CoV).
Full text loading...
Approach to diagnosis of suspected viral respiratory tract infection.
Epidemiology, diagnosis, and therapy for respiratory viral infections in transplant recipients
FDA-approved rapid diagnostic tests for influenza
FDA approved rapid diagnostic tests for RSV
Sensitivity of R-Mix cell cultures in detecting specific respiratory viruses b
Detection of respiratory viruses by MAbs versus reverse transcription-PCR a